Boston Scientific (NYSE:BSX) has been assigned a $33.00 target price by stock analysts at SunTrust Banks in a research report issued to clients and investors on Monday. The firm presently has a “buy” rating on the medical equipment provider’s stock. SunTrust Banks’ price target suggests a potential upside of 32.32% from the company’s previous close.

A number of other brokerages have also recently commented on BSX. BMO Capital Markets reiterated a “buy” rating and issued a $31.00 target price on shares of Boston Scientific in a report on Wednesday, November 29th. Cowen set a $31.00 target price on Boston Scientific and gave the stock a “buy” rating in a report on Thursday, November 30th. Oppenheimer reiterated a “hold” rating on shares of Boston Scientific in a report on Wednesday, November 29th. BTIG Research upgraded Boston Scientific from a “neutral” rating to a “buy” rating and set a $31.00 target price for the company in a report on Thursday, November 30th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $32.00 target price on shares of Boston Scientific in a report on Monday, September 25th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $30.56.

Shares of Boston Scientific (BSX) traded up $0.04 on Monday, reaching $24.94. The company had a trading volume of 15,065,687 shares, compared to its average volume of 6,946,950. The company has a market cap of $34,320.00, a P/E ratio of 21.43, a PEG ratio of 2.02 and a beta of 0.95. Boston Scientific has a 52 week low of $20.36 and a 52 week high of $29.93. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.31. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The business had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the previous year, the company posted $0.27 EPS. The company’s revenue was up 5.6% compared to the same quarter last year. equities research analysts predict that Boston Scientific will post 1.25 EPS for the current year.

In related news, EVP Timothy A. Pratt sold 10,000 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $26.04, for a total transaction of $260,400.00. Following the transaction, the executive vice president now directly owns 154,681 shares of the company’s stock, valued at approximately $4,027,893.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy A. Pratt sold 11,061 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $29.24, for a total value of $323,423.64. Following the transaction, the executive vice president now directly owns 174,681 shares in the company, valued at $5,107,672.44. The disclosure for this sale can be found here. Over the last three months, insiders sold 424,698 shares of company stock valued at $12,273,553. Corporate insiders own 0.74% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Swiss National Bank boosted its stake in shares of Boston Scientific by 2.9% in the second quarter. Swiss National Bank now owns 5,584,930 shares of the medical equipment provider’s stock worth $154,814,000 after buying an additional 156,800 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Boston Scientific by 10.5% in the second quarter. Wells Fargo & Company MN now owns 9,157,768 shares of the medical equipment provider’s stock worth $253,854,000 after buying an additional 867,983 shares during the last quarter. Sit Investment Associates Inc. boosted its stake in shares of Boston Scientific by 37.8% in the third quarter. Sit Investment Associates Inc. now owns 141,710 shares of the medical equipment provider’s stock worth $4,134,000 after buying an additional 38,855 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its stake in shares of Boston Scientific by 35,016.2% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock worth $84,337,000 after buying an additional 3,033,800 shares during the last quarter. Finally, Greenwood Capital Associates LLC boosted its stake in shares of Boston Scientific by 71.7% in the third quarter. Greenwood Capital Associates LLC now owns 91,579 shares of the medical equipment provider’s stock worth $2,671,000 after buying an additional 38,249 shares during the last quarter. Institutional investors and hedge funds own 90.57% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Boston Scientific (BSX) Given a $33.00 Price Target at SunTrust Banks” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/05/boston-scientific-bsx-given-a-33-00-price-target-at-suntrust-banks.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.